Copyright
©The Author(s) 2017.
World J Gastroenterol. Dec 14, 2017; 23(46): 8120-8127
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8120
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8120
Table 1 Representative direct-acting antivirals, their targets and hepatitis C virus genotypes
Target regions | DAAs | HCV GTs |
NS3/4A | Glecaprevir | Pan-GTs |
Grazoprevir | 1, 4 | |
Asunaprevir | 1b | |
Paritaprevir | 1, 2a, 4 | |
Simeprevir | 1, 4 | |
Telaprevir | 1, 2 | |
Boceprevir | 1 | |
NS5A | Pibrentasvir | Pan-GTs |
Velpatasvir | Pan-GTs | |
Elbasvir | Pan-GTs | |
Daclatasvir | Pan-GTs | |
Ledipasvir | 1, 4, 5 | |
Ombitasvir | 1, 4 | |
NS5B | Sofosbuvir [nucleos(t)ide inhibitor] | Pan-GTs |
Dasabuvir [non-nucleos(t)ide inhibitor] | 1 |
- Citation: Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127
- URL: https://www.wjgnet.com/1007-9327/full/v23/i46/8120.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i46.8120